BACM
CYTK icon

Blue Arrow Capital Management’s Cytokinetics CYTK Stock Holding History

Blue Arrow Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-30,000
Closed -$240K – 175
2014
Q4 		$240K Buy
+30,000
New +$129K 0.03% 169

Other funds holding CYTK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPU
Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
IIM
Ironwood Investment Management Boston, Massachusetts $240M AUM 45.82% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Blue Arrow Capital Management's CYTK Position: Q1 2015 in Review

Blue Arrow Capital Management sold out of Cytokinetics (CYTK) in Q1 2015, closing a stake of 30,000 shares — an estimated $240K sold.

Blue Arrow Capital Management first reported a position in CYTK in Q4 2014 and held it in 1 quarter. The position peaked at $240K in Q4 2014. 94 funds tracked by Wall St. Rank hold CYTK as of Q1 2015.

  • Blue Arrow Capital Management reported no remaining Cytokinetics position as of Q1 2015 after selling out during the quarter.
  • Blue Arrow Capital Management sold 30,000 Cytokinetics shares in Q1 2015, an estimated $240K.
  • Blue Arrow Capital Management first reported a position in Cytokinetics in Q4 2014 and held it in 1 quarter.
  • Blue Arrow Capital Management's Cytokinetics position peaked at $240K in Q4 2014.
  • 94 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2015.

Based on Blue Arrow Capital Management's 13F filing for Q1 2015, filed 15 May 2015.